Document is current
Any future updates will be listed below
-
Authors
Elliott, Mitchell J. https://orcid.org/0000-0001-6711-7287
Ennis, Marguerite
Pritchard, Kathleen I. https://orcid.org/0000-0003-0758-9666
Townsley, Carol
Warr, Dave
Elser, Christine
Amir, Eitan https://orcid.org/0000-0002-3706-525X
Bedard, Philippe L.
Rao, Lakshmi
Stambolic, Vuk
Sridhar, Srikala https://orcid.org/0000-0002-6994-1285
Goodwin, Pamela J. https://orcid.org/0000-0003-2637-6906
Cescon, David W. https://orcid.org/0000-0002-1080-0998
-
Funding
Funding for this research was provided by:
Breast Cancer Research Foundation
- License Information
-
More Information
Article History
Received: 1 October 2019
Accepted: 11 May 2020
First Online: 12 June 2020
Competing interests
: M.J.E., M.E., K.I.P, C.T., D.W., C.E., L.R., V.S., and S.S. do not have any conflicts of interest related to this work. P.J.G. has received research support (to institution) from Epic Sciences, Breast Cancer Research Fund (BCRF), and Hold’Em for Life Charity. E.A. has provided expert testimony for Genentech and Roche; and consultation for Sandoz and Apobiologix. P.B. has provided consultation for Bristol Myers Squibb, Sanofi and Pfizer; and has received research support (to institution) from AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline, Roche/Genentech, Novartis, Sanofi, Seattle Genetics, Servier, SignalChem, PTC Therapeutics, Nektar, Merck, Mersana and Eli Lilly and Co. D.W.C. has provided consultation for Agendia, AstraZeneca, GlaxoSmithKline, Merck, Novartis, Pfizer, Puma, Roche and Dynamo Therapeutics; received research support (to institution) from GlaxoSmithKline, Merck and Pfizer; and is listed as a co-inventor on a patent related to biomarkers for TTK inhibitors.
